Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04733118
Title Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Acronym PHERGAIN-2
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedSIR
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA | HUN | ESP | DEU | BGR


No variant requirements are available.